Welcome to LookChem.com Sign In|Join Free

CAS

  • or

917-93-1

Post Buying Request

917-93-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

917-93-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 917-93-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 9,1 and 7 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 917-93:
(5*9)+(4*1)+(3*7)+(2*9)+(1*3)=91
91 % 10 = 1
So 917-93-1 is a valid CAS Registry Number.
InChI:InChI=1/C4H7ClO/c1-4(2,5)3-6/h3H,1-2H3

917-93-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-chloro-2-methylpropanal

1.2 Other means of identification

Product number -
Other names 2-Chloro-2-methylpropionaldehyde

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:917-93-1 SDS

917-93-1Relevant articles and documents

-

Lorenzini,Walling

, p. 4008 (1967)

-

PROCESS FOR THE PREPARATION OF 2,2-DIMETHYLPIPERAZINE

-

Page/Page column 10; 11; 12, (2019/10/29)

This invention relates to a novel chemical process for the synthesis of 2,2-dimethylpiperazine and the further transformation of 2,2-dimethylpiperazine into ferf-butyl-3,3-dimethylpiperazine-l- carboxylate-hemi-DL-tartrate.

INHIBITORS OF BETA-SECRETASE

-

Paragraph 0199-0200, (2014/03/24)

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 917-93-1